European Patent Board Rules in Favour of Puma Biotechnology - IP News Shots
Puma Shares Soar 81% Over 2 Days | Los Angeles Business Journal
Here's Why Puma Biotechnology Tumbled Today | The Motley Fool
Puma Biotechnology Inc
PUMA BIOTECHNOLOGY: FDA Approves Labeling Supplement for Puma Biotechnology's NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer | FDA Health News
Puma Biotechnology
$51.61 Million in Sales Expected for Puma Biotechnology, Inc. (NASDAQ:PBYI) This Quarter - Opera News
Puma Biotechnology
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | FiercePharma
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ… https://t.co/sWLJCNJzQV"
Puma Biotechnology
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Here's Why Puma Biotechnology Inc (NASDAQ:PBYI) Is Running Up - Market Exclusive